Immatics (IMTX) Current Deferred Revenue (2019 - 2025)
Immatics recorded quarterly Current Deferred Revenue of $21.6 million in Q4 2025, down 27.78% quarter-over-quarter from $29.9 million in Q3 2025, and down 43.75% year-over-year from $38.4 million in Q4 2024.
Immatics' Current Deferred Revenue history runs 7 years deep, the most recent figure standing at $21.6 million for Q4 2025.
- In Q4 2025, Current Deferred Revenue fell 43.75% year-over-year to $21.6 million; the TTM figure through Dec 2025 stood at $21.6 million (down 43.75% YoY), while the FY2025 annual figure was $20.9 million, down 45.41% from the prior year.
- Current Deferred Revenue came in at $21.6 million for Q4 2025 at Immatics, down from $29.9 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $124.3 million in Q4 2023 to a low of $21.6 million in Q4 2025.
- A 5-year average of $71.6 million and a median of $73.5 million in 2021 frame the typical range for Current Deferred Revenue.
- Across the five-year window, Current Deferred Revenue surged 87.56% in 2023 and sank 70.74% in 2025, its largest moves.
- Immatics' Current Deferred Revenue stood at $57.7 million in 2021, then climbed by 14.94% to $66.3 million in 2022, then soared by 87.56% to $124.3 million in 2023, then sank by 69.13% to $38.4 million in 2024, then sank by 43.75% to $21.6 million in 2025.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $21.6 million, $29.9 million, and $31.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Immatics | 1.80 Bn | 1.80 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 21.58 Mn |
| Sep 30, 2025 | 29.88 Mn |
| Jun 30, 2025 | 31.20 Mn |
| Mar 31, 2025 | 30.68 Mn |
| Dec 31, 2024 | 38.37 Mn |
| Sep 30, 2024 | 75.70 Mn |
| Jun 30, 2024 | 102.87 Mn |
| Mar 31, 2024 | 104.86 Mn |
| Dec 31, 2023 | 124.30 Mn |
| Sep 30, 2023 | 67.55 Mn |
| Jun 30, 2023 | 74.04 Mn |
| Mar 31, 2023 | 70.07 Mn |
| Dec 31, 2022 | 66.27 Mn |
| Sep 30, 2022 | 104.07 Mn |
| Jun 30, 2022 | 123.05 Mn |
| Mar 31, 2022 | 76.08 Mn |
| Dec 31, 2021 | 57.66 Mn |
| Sep 30, 2021 | 72.97 Mn |
| Jun 30, 2021 | 74.91 Mn |
| Mar 31, 2021 | 86.50 Mn |
| Dec 31, 2020 | 101.91 Mn |
| Sep 30, 2020 | 93.79 Mn |
| Jun 30, 2020 | 90.91 Mn |
| Dec 31, 2019 | 51.58 Mn |